Interim thymus and activation regulated chemokine versus interim ¹⁸ F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.

ABSTRACT: Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim ¹⁸ F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.

SUBMITTER: Plattel WJ 

PROVIDER: S-EPMC7383815 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature